The peculiarities of cytokine status in children suffering from persistent allergic rhinitis during early stages of allergenspecific immunotherapy



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. To study dynamics of cytokine status during early stages of allergen-specific immunotherapy (ASIT) in children suffering from persistent allergic rhinitis (PAR).
Methods. 30 children suffering from PAR have received complete course of ASIT. Serum levels ofILL-4, -5, -6, -8, -12, -13, sIL-2R were studied in 0, 7, 30 and 90 days and have been analyzed differentially in groups with good/excellent and incomplete effectiveness of treatment.
Results. Good/excellent effectiveness of completed course of ASIT has been demonstrated in 17/30 (56,7%) children, partial effectiveness has been demonstrated for 13/30 (43,3%) ones.The decreased IL-12 and IL-6 levels and the increase of sIL-2R production were described for good/excellent results of treatment, but insufficient effectiveness was characterized by delayed dynamics of these cytokines. IL-8 level was increased in both groups but decreased effectiveness was associated with early start and long duration of it. IL-4 production was decreased in the good/ excellent group while on the second one changes of cytokine level were absent. IL-13 and IL-5 synthesis were increased in both groups.
Conclusion. The effectiveness of ASIT in PAR patients depends on synthesis dynamics of ILL-4, -6, -8, -12, sIL-2R at the early treatment stages.

About the authors

E B Belan

Volgograd State Medical University, Russia Consuting-Diagnostic Polyclinic No. 2

Email: belan05@mail.ru
Volgograd State Medical University, Russia Consuting-Diagnostic Polyclinic No. 2

T L Sadchikova

Volgograd State Medical University, Russia Consuting-Diagnostic Polyclinic No. 2

Volgograd State Medical University, Russia Consuting-Diagnostic Polyclinic No. 2

Uy V Antonov

Volgograd State Medical University, Russia Consuting-Diagnostic Polyclinic No. 2

Volgograd State Medical University, Russia Consuting-Diagnostic Polyclinic No. 2

References

  1. Canonica W., Baena-Cagnani C.E., Bousquet J. etc. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. Allergy 2007, v. 62, p. 317-324.
  2. Ciprandi G., Marseglia G.L., Tosca M.A. A statement of a World Allergy Organization (WAO) taskforce Monaldi Arch. Chest. Dis. 2006, v. 65 (1), p. 34-37. Ciprandi1 G., Marseglia G.L., Tosca M.A. Allergen-specific immunotherapy: an update on immunological mechanisms of action. Monaldi Arch. Chest. Dis. 2006, v. 65 (1), p. 34-37.
  3. Akdis M., Akdis C. A. Mechanisms of allergen-specific im-munotherapy. J. Allergology Clin. Immunol. 2007, v. 119 (issue 4), p. 780-789.
  4. Аллергический ринит и его влияние на астму (ARIA): Руководство для врачей и мед. сестер. М., 2001, 24 с.
  5. Гущин И. С. Аллерген-специфическая иммунотерапия атопических заболеваний: пособие для врачей. М., 2002, 32 с.
  6. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J. Allergy Clin. Immunol. 2007, v. 120 (3 Suppl), p. 25-85.
  7. Fujisawa T., Nagao M., Hosoki Yu. etc. Biomarkers for allergen immunotherapy in cedar pollinosis. Allergology Int. 2009, v. 58, № 2, p. 163-170.
  8. Arshad S.H. Primary prevention of asthma and allergy.
  9. J. Allergy Clin. Immunol. 2005, v. 116, p. 3-144.
  10. Dahl R. Specific immunotherapy with SQ standardized grass allergen tadlets in asthmatics with rhinoconjunctivitis. Allergy. 2006, v. 61, p. 185-191.
  11. Silny W. et al. Immunological parameters in the sera of patients with atopic dermatitis and airborne allergy treated with allergy vaccines. Acta dermatovenerologica Croatica. 2006, v. 14 (issue 1), p. 8-20.
  12. Park H.S. Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen. Ann Allergy, Asthma Immunol. 2001, v. 86, No. 4, p. 444-448.
  13. Okamoto Hideki. Clinical efficacy and immunological mechanisms of immunotherapy for perennial allergic rhinitis. Journal of the Osaka Citi Medical. Center. 2000, v. 47, p. 401-426.
  14. Silny W. Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomosci lekarskie 2005, v. 58 (5-6), p. 287-294.
  15. Silny W. Specific immunotherapy in the treatment of patients with atopic dermatitis - results of double blind placebo controlled study. Pol. Merkur. Lekarski, 2006, v. 21 (126), p. 558-565.
  16. Kue-Hsiung H. Decreased production of interleukin-2 receptors after immunotherapy to house dust. J. Clin. Immunol. 1988, v. 8 (3), p. 171-177.
  17. Jacobi H., Poulsen L.K., Reimert C.M. etc. IL-8 and the activation of eosinophils and neutrophils following nasal allergen challenge. Int. Arch. Allergy Immunol. 1998, v. 116, p. 53-59.
  18. Andersson T.N., Ekman G.J., Gronlund H. et al. A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro. Immunology. 2004, v. 113 (2), p. 253-259.
  19. Toshiyuki Tazaki, Kenji Minoguchi, Takuya Yokoe et al. Allergen rush immunotherapy increases interleukin (IL)-12 production and IL-12 receptor β2 chain expression in patients with allergic asthma. Cell Immunol. 2004, v. 228 (1), p. 20-26.
  20. Grzela K., Grzela T., Lazarczyk M. et al. Influence of allergen-specific immunotherapy on IL-4-dependent IL-12 production by monocytes. Int. J. Mol. Med. 2002, v. 10, No. 4, p. 481-484.
  21. EL-Naggar, Ukai, Takeuchi et al. Effect of Allergen-Specific Immunotherapy on Interleukin-4, Interleukin-5 and Inter-feron-γ mRNA Expression in the Nasal Mucosa of Rats with Allergic Rhinitis. Scand. J. Immunol. 1998, v. 48 (issue 6), p. 629-634.
  22. Macaubas C., N.H. de Klerk, Holt B.J. et al. Association between antenatal cytokine production and the development of atopy and asthma at age 6 years. Lancet. 2003, v. 362, p. 1192-1197.
  23. Jutel M., Akdis M., Blaser K., Akdis C.A. Mechanisms of allergen specific immunotherapy-T-cell tolerance and more. Allergy. 2006, v. 61 (7), p. 796-807.
  24. Moverare R. Allergen-specific increase in IL-4 and IL-5 secretion from peripheral blood mononuclear cells during brich-pollen immunotherapy. Allergy. 2007, v. 53, Issue 3, p. 275-281.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies